
    
      The primary objective of this study is to assess the safety and efficacy of the BACE device
      for the treatment of FMR.

      Secondary objective is to assess the ease of deployment of the BACE device Study Population:
      Since this study is to assess the safety and efficacy of a new device, with no control arm or
      comparator, the number of subjects enrolled will be a maximum of 60.

      Approximately 8-10 sites are expected to be included in the study. The subject population is
      adults of 18 to 80 years of age, either gender, with FMR as specified in the inclusion and
      exclusion criteria.
    
  